facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2019
vol. 106
 
Share:
Share:
abstract:
Special paper

Vitiligo. Diagnostic and therapeutic recommendations of the Polish Dermatological Society

Rafal Czajkowski
1
,
Waldemar Placek
2
,
Iwona Flisiak
3
,
Dorota Krasowska
4
,
Joanna Maj
5
,
Mariola Marchlewicz
6
,
Adam Reich
7
,
Hanna Wolska
8
,
Lidia Rudnicka
9

  1. Department of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
  2. Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury, Olsztyn, Poland
  3. Department of Dermatology and Venereology, Medical University of Bialystok, Poland
  4. Chair and Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Poland
  5. Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland
  6. Department of Aesthetic Dermatology, Pomeranian Medical University, Szczecin, Poland
  7. Department of Dermatology, University of Rzeszow, Poland
  8. High-Med Specialist Clinic, Warsaw, Poland
  9. Department of Dermatology, Medical University of Warsaw, Poland
Dermatol Rev/Przegl Dermatol 2019, 106, 1–15
Online publish date: 2019/03/19
View full text Get citation
 
PlumX metrics:
Vitiligo is an idiopathic chronic dermatosis manifested by depigmented patches of skin due to the loss of normal pigment-producing cells (melanocytes) and pigment (melanin). The disease develops more commonly in genetically predisposed individuals affected by various adverse external and internal factors inducing cellular stress in melanocytes. Cellular stress activates autoimmune and autoinflammatory mechanisms leading to melanocyte destruction. The disorder affects 0.5–4.0% of the world population, with no predilection for either sex. Manifestations can appear at any age, however in more than half of patients vitiligo starts before the age of 20 years. The course of the disease is varied – from stable cases with small isolated vitiligo patches to the rapid progression of lesions resulting in large areas of the skin being affected. There are multiple methods of treating vitiligo including pharmacological and surgical modalities, and phototherapy. Another essential aspect is patient education. Available treatment methods do not always yield the expected therapeutic effect. The Recommendations contain information about the diagnosis of vitiligo, and describe the recommended therapeutic methods.
keywords:

vitiligo, treatment



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.